Kaituo Pharmaceutical-B (09939): KT-939 obtained a notice granting a patent for an invention

Zhitong Finance App News, Kaituo Pharmaceutical-B (09939) issued an announcement. On October 21, 2026, the Group received a notice granting an invention patent from the State Intellectual Property Office of China for KT-939 (Chinese product name: OXIMIDOL® KT-939, English product name: OXIMIDOL® KT-939), a novel self-developed high-efficiency tyrosinase inhibitor that inhibits melanin production. This patent relates to a tyrosinase inhibitor and its use (Application No.: 202580002670.3). Suzhou Kaituo Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the Company, submitted a priority review request on March 27, 2026, and was granted priority review by the State Intellectual Property Office of China on June 12, 2026. It took about 6 months from the submission of the priority examination to the issuance of the notice granting the patent for the invention.

Currently, the company is undergoing subsequent authorization registration procedures in accordance with applicable law. According to the claim text to be authorized this time, the specific chemical structure of KT‑939 (Chinese product name: OXIMIDOL® KT-939, English product name: OXIMIDOL® KT-939) is not only covered by the specific compound claims in the patent application, but also falls within the scope of protection of its general compound claims, and is the object of protection to be protected by this patent application.

KT-939 is our core commercial product. The KT-939 invention patent has been authorized in China and is expected to help strengthen KT-939's competitive advantage in the high-end cosmetic ingredients market for whitening and freckle removal. The company submitted all registration application data for KT-939 as an effective cosmetic ingredient to the China National Drug Administration (CFDA) on September 18, 2026, and will seek approval from the State Drug Administration as soon as possible.

Furthermore, the company is developing an analogue of KT-939 as an innovative topical drug to treat diseases related to abnormal pigmentation, such as melasma.